Evidence in Action: Advancing Care for Angina with Shockwave Reducer
At EuroPCR 2026, anchorperson Rasha Al-Lamee, spokesperson Tommaso Gori, and discussants Ranil de Silva, Oriol Rodriguez Leor, Mariusz Tomaniak, and Mike Foley took the stage to present “Evidence in Action: Advancing Care for Angina with Shockwave Reducer”
Speakers:
- Dr. Ranil de Silva – Royal Brompton Hospital, London
- Dr. Oriol Rodriguez Leor – Hospital Universitari Germans Trias i Pujol, Barcelona
- Prof. Mariusz Tomaniak – Medical University of Warsaw, Warsaw
- Dr. Mike Foley – Imperial College Healthcare NHS Trust, London
The True Prevalence and Impact of Angina
Dr. Ranil de Silva provides an overview of the definition, prevalence, challenges and impact of refractory angina on patients’ lives and healthcare systems. He describes the spectrum of angina patients and the types of therapies that may be most appropriate to meet their needs.
Current and Future Clinical Data Supporting the Use of the Shockwave Reducer in Obstructive Disease
Tune in to watch Dr. Oriol Rodriguez Leor review the clinical evidence from multiple Shockwave Reducer studies. He covers the existing evidence for obstructive disease as well as the consistency in results across procedural success, safety, and multiple measures of quality of life. He also highlights important ongoing studies and their potential future impact on the understanding and treatment of angina.
Current and Future Clinical Data Supporting the Use of the Shockwave Reducer in Non-Obstructive Disease
Join Prof. Mariusz Tomaniak as he explores the growing importance of treating angina in patients with non-obstructive disease via a case study. He then reviews the latest clinical results on Shockwave Reducer use in non-obstructive coronary arteries (ANOCA)/ischemia with no obstructive coronary arteries (INOCA) patients. He also discusses the upcoming results from ongoing trials which will provide significant clinical and mechanistic insights for this undertreated patient group.
Shockwave Reducer’s Unique Mechanism of Action and clinical impact on patients with angina
Dr. Mike Foley reviews the hypothesized MOA of the Shockwave Reducer device and the mechanistic insights drawn from the ORBITA-COSMIC clinical study. Additionally, he provides details on the clinical and real-life quality of life changes potentially made possible with Shockwave Reducer.
Individual patient stories. Results may vary.
The physicians featured are paid consultants of Shockwave Medical. Views expressed are those of the authors and not necessarily those of Shockwave Medical.
Shockwave Reducer is commercially available in select European countries and has been implanted in over 3,500 patients. It is currently under clinical investigation in the U.S.
CAUTION: In the United States, Shockwave Reducer is an investigational device, limited by United States law to investigational use. Shockwave Reducer is subject of investigational testing and is being studied in the COSIRA-II trial in Canada. Shockwave Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability. Prior to use, please reference the Instructions for Use for more information on warnings, precautions and adverse events: ifu.sw-reducer.com
